Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-04T21:22:31.528Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of psychotropic switches on weight change: a prospective cohort study

Published online by Cambridge University Press:  01 September 2022

M. Piras ,
S. Ranjbar ,
C. Dubath ,
N. Laaboub ,
C. Grosu ,
F. Gamma ,
K. Von Plessen ,
A. Von Gunten ,
P. Conus  and
C. Eap
M. Piras*
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
S. Ranjbar
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
C. Dubath
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
N. Laaboub
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
C. Grosu
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
F. Gamma
Affiliation:
Les Toises Psychiatry and Psychotherapy Center, Psychiatry, Lausanne, Switzerland
K. Von Plessen
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
A. Von Gunten
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
P. Conus
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
C. Eap
Affiliation:
Lausanne University Hospital, Psychiatry, Prilly, Switzerland
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Many psychotropic drugs can induce weight gain with differences in their metabolic risk profiles (i.e. high, medium or low-risk).

Objectives

To compare the weight evolution of patients switching versus patients keeping their psychotropic drugs with different risk-profiles.

Methods

Data for patients switching or keeping the same drug were obtained from the Psyclin (from 2007 to 2015) and Psymetab (2007- 2019) cohort studies, conducted at the Lausanne University Hospital, Switzerland. Patients either switched from a high to a low-risk, a high to a medium-risk, a medium to a low-risk drug, or for a drug with the same risk category. Patients not switching either kept a high, medium or low-risk drug. The evolution of weight is currently being analyzed using a linear mixed-effect model.

Results

Preliminary results showed that switching from a high to low-risk molecule had the strongest impact on weight changes. The analysis being ongoing, the quantitative results will be presented at the congress.

Conclusions

Switching from a high-risk to a low-risk molecule is likely to have the strongest impact on weight changes.

Disclosure

No significant relationships.

Keywords

psychopharmacologyWeight gain
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S731
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.